| Dr Samuel Clayton Korbe, MD | |
|
6475 S Yale Ave Ste 308, Tulsa, OK 74136-7802 | |
| (918) 502-9650 | |
| (918) 502-9655 |
| Full Name | Dr Samuel Clayton Korbe |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 13 Years |
| Location | 6475 S Yale Ave Ste 308, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912297805 | NPI | - | NPPES |
| 200649440B | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 31892 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital, Inc | Tulsa, OK | Hospital |
| Saint Francis Hospital South, Llc | Tulsa, OK | Hospital |
| Saint Francis Hospital Muskogee | Muskogee, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Warren Clinic Inc | 8820900293 | 604 |
News Archive
Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 7 days ago
| Entity Name | Warren Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174582282 PECOS PAC ID: 8820900293 Enrollment ID: O20031104000252 |
News Archive
Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samuel Clayton Korbe, MD 6600 S Yale Ave Ste 1400, Tulsa, OK 74136-3331 Ph: (888) 247-0125 | Dr Samuel Clayton Korbe, MD 6475 S Yale Ave Ste 308, Tulsa, OK 74136-7802 Ph: (918) 502-9650 |
News Archive
Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.
INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
› Verified 7 days ago
Dr. Andrew Lott Barker, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 10505 E 91st St, Suite 205, Tulsa, OK 74133 Phone: 918-307-5470 | |
Bhadresh L Bhakta, MD Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 8556 E 101st St, Suite A, Tulsa, OK 74133 Phone: 918-369-5511 Fax: 918-369-5512 | |
Dr. David W Asher, DO Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 1836 E 15th St, Tulsa, OK 74104 Phone: 918-744-0110 Fax: 918-744-0110 | |
Venkatesh Movva, MD Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 6565 S Yale Ave, #212, Tulsa, OK 74136 Phone: 918-502-4000 Fax: 918-502-4001 | |
Stephen Thomas Lester, MD Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 6585 S Yale Ave, Ste 1110, Tulsa, OK 74136 Phone: 918-502-7246 Fax: 918-502-7250 | |
Dr. Frank Joseph Hackl, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 7901 S Sheridan Rd, Tulsa, OK 74133 Phone: 918-710-4112 Fax: 918-710-4118 |